Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new antiplatelet drug outperform clopidogrel after a heart attack?

NCT ID NCT06577519

Disease control Sponsor: Jiangsu vcare pharmaceutical technology co., LTD Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This phase III trial tests whether vicagrel, an experimental antiplatelet drug, can prevent major heart-related events better than the standard drug clopidogrel in people with acute coronary syndrome (such as a heart attack or unstable angina) who are undergoing a stent procedure. About 1,000 participants will receive either vicagrel or clopidogrel, and researchers will track the rate of heart attacks, strokes, and cardiovascular deaths over time. The goal is to see if vicagrel offers stronger protection without increasing dangerous bleeding.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
vicagrel, an experimental antiplatelet drug
What this could lead to
If vicagrel proves more effective than clopidogrel, it could offer a new option to prevent heart attacks and strokes in people with acute coronary syndrome who receive a stent.
What could go wrong
This is a phase III trial, but vicagrel is still experimental. It may not be safer or more effective than the standard drug, and like all antiplatelet agents, it carries a risk of bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients between 18 and 80 years old, with no gender restrictions. * Patients diagnosed with ACS and scheduled for PCI, including STEMI and NSTE-ACS (UA/NSTEMI). * Voluntarily sign the ICF and be able to follow the visit arrangements specified in the protocol during the trial period. Exclusion Criteria: * Expected survival time\<12 months; * Severe liver dysfunction (non heart disease induced ALT or AST\>3x ULN) and cirrhosis; * Pregnant or lactating women, or participants and their partners who plan to become pregnant during the trial period; * The researchers determined that other reasons were not suitable for participants in this experiment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute coronary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • General Hospital of Northern Theater Command of Chinese PLA

    RECRUITING

    Shenyang, Liaoning, 110015, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.